Royalty Pharma plc
RPRX
$53.25
$1.553.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -24.35% | -10.13% | -33.11% | 51.76% | 36.89% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 51.39% | 46.39% | 38.25% | 27.43% | 4.97% |
| Total Other Non-Cash Items | -10.58% | -44.13% | -16.34% | -93.13% | -48.02% |
| Change in Net Operating Assets | 10.40% | 9.91% | 6.62% | 8.36% | 9.70% |
| Cash from Operations | -3.28% | -10.08% | -14.07% | -9.85% | 3.12% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -20.79% | 42.51% | 62.25% | 41.08% | -30.40% |
| Cash from Investing | -24.35% | 39.73% | 59.91% | 38.03% | -30.40% |
| Total Debt Issued | 119.51% | 119.51% | 77.32% | -100.00% | 320.35% |
| Total Debt Repaid | -- | -- | -550.00% | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 39.40% | -434.46% | -478.76% | -359.42% | -207.93% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -2.48% | -0.47% | -1.46% | -2.30% | -3.99% |
| Other Financing Activities | 1.38% | -6.12% | -3.40% | -1.28% | -8.47% |
| Cash from Financing | -40.52% | -428.39% | -395.53% | -214.27% | 82.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -304.86% | -168.65% | -181.65% | -177.34% | 121.61% |